Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 2

Company Profile

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the research, development, and advancement of immunomodulatory therapies for the treatment of pain from osteoarthritis. The Company’s lead product candidate, Ampion has immunomodulatory action and anti-inflammatory effects, which provide a treatment for individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (OAK); osteoarthritis related to other joints, such as hip, shoulder, ankle and hand; and the widespread inflammation associated with COVID-19 infection. Ampion is in development as an intra-articular injection treatment for severe OAK, an intravenous (IV) and inhaled treatment for hospitalized severe and/or critical COVID-19 patients, and an at-home inhalation treatment for patients with prolonged respiratory symptoms due to COVID-19, referred to as Long-COVID. Its clinical studies include AP-013, AP-017, AP-019 and AP-018.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan